Feasibility of Outpatient High-Dose Methotrexate Infusions in Pediatric Patients With B-Lineage Acute Lymphoblastic Leukemia
- PMID: 30719391
- PMCID: PMC6347087
Feasibility of Outpatient High-Dose Methotrexate Infusions in Pediatric Patients With B-Lineage Acute Lymphoblastic Leukemia
Abstract
High-dose methotrexate (MTX) given in four hospitalizations during interim maintenance for high-risk pediatric B-lineage acute lymphocytic leukemia significantly improves survival but increases resource utilization. Children remain hospitalized for intravenous hydration and blood or urine monitoring until MTX clearance parameters are reached. Improved supportive care, extended infusion center hours, and pediatric home health expertise afford alternatives to prolonged hospital admissions, potentially offering quality, cost-effective approaches that positively impact the delivery of care.
Figures
References
-
- American Cancer Society. Economic impact of cancer. 2018 Retrieved from https://www.cancer.org/cancer/cancer-basics/economic-impact-of-cancer.html.
-
- Larsen E C, Salzer W L, Devidas M, Nachman J B, Raetz E A, Loh M L, Carroll W L. Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children’s Oncology Group Study AALL0232 [Abstract 3]. Journal of Clinical Oncology. 2011;29(15_suppl)
-
- Mahadeo Kris M, Santizo Ruth, Baker Lindsay, Curry Joan O'Hanlon, Gorlick Richard, Levy Adam S. Ambulatory high-dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost-effective. Pediatric blood & cancer. 2010;55:1296–1299. - PubMed
Publication types
LinkOut - more resources
Full Text Sources